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Endovascular treatment improves cognitive function after 
ischemic stroke. A secondary analysis of REVASCAT trial 
 
 
Abstract 
 
Objective: We aimed to investigate the effect of endovascular treatment on cognitive 
function as a pre-specified secondary analysis of the REVASCAT trial. Methods: 
REVASCAT (NCT01692379) randomized 206 patients with anterior circulation 
proximal arterial occlusion stroke to Solitaire® thrombectomy or best medical treatment 
alone. Patients with established dementia were excluded from enrollment. Cognitive 
function was assessed in person with Trail Making Test (TMT) parts A and B at three 
months and one year after randomization, by an investigator masked to treatment 
allocation. Test completion within 5 minutes, time of completion(seconds)and number 
of errors were recorded. Results: From November 2012 to December 2014, 206 
patients were enrolled in REVASCAT trial. TMT was assessed in 82/84 thrombectomy 
and in 86/87 control patients alive at three months and in 71/79 thrombectomy and in 
72/78 control patients alive at one year. Rates of timely TMT-A completion were 
similar in both treatment arms although thrombectomy patients required less time for 
TMT-A completion and had higher rates of error-free TMT-A performance; 
thrombectomy was also associated with higher probability of timely TMT-B completion 
(adjusted OR, 95% CI; 3·17[1·51, 6·66] at three months and 3·66[1·60-8·35] at one 
year) and shorter time for TMT-B completion. Differences in TMT completion times 
among treatment arms were significant in patients with good functional outcome, but 
not in those functionally dependent (modified Rankin Scale>2). Poorer cognitive 
outcomes were significantly associated with larger infarct volume, higher modified 
Rankin scores and worse quality of life. Conclusions: Thrombectomy improves TMT 
performance after stroke, especially among patients who reach good functional 
recovery.  Classification of Evidence: This study provides Class I evidence that for 
patients with stroke from acute anterior circulation proximal arterial occlusion, 
thrombectomy improves performance on the Trail Making Test at 3 months. 
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Introduction:  
Cognitive impairment is a common consequence of stroke, 1–3even in survivors with 
successful functional recovery,4 and it is closely related to disability and dependency. 2 
Cognitive impairment and dementia following stroke may involve multiple domains, 
attention and executive functioning being particularly affected.1, 3Altered executive 
functioning early after stroke has been reported as a predictor of long-term cognitive 
impairment. 5 
Because cognitive outcome has traditionally not been considered as outcome measure in 
randomized trials investigating the benefit of intravenous t-PA in acute stroke, little 
knowledge exists with regards to any potential benefit intravenous t-PA may have on 
cognition. In a recent post-hoc analysis based on pooled data from the VISTA trials, 
Cog-4 scale (based on four items of NIH stroke scale) was used as an indicator of 
cognitive function at three months after stroke. It was noted that the distribution of Cog-
4 scores was better in patients who received intravenous rTPA compared to those that 
were not thrombolysed, although this scale did not provide additional information 
beyond the modified Rankin Scale (mRS) assessment. 6 
Endovascular treatment has recently demonstrated benefit in physical disability and 
functional outcome after acute stroke 7 but the effect on cognitive outcomes has not 
been established yet.  REVASCAT (RandomizEd trial of reVasculArization with 
SOLITAIRE FR® device  (Covidien-Medtronic, Minneapolis, USA) versus best 
mediCal therapy in the treatment of Acute stroke due to anTerior circulation large 
vessel occlusion presenting within eight-hours of symptom onset) randomized acute 
stroke patients either to medical therapy plus endovascular treatment thrombectomy or 
to medical treatment alone. Analysis of the third month primary outcome consisting of 
ordinal mRS score analysis revealed that thrombectomy was beneficial.8 
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A pre-specified secondary outcome of REVASCAT 9 was to evaluate the effect of 
endovascular treatment on cognitive functioning at three months and one year after 
stroke as measured by the Trail Making Test. We also aimed to study the relationship 
among cognitive outcomes and other stroke relevant outcomes (infarct volume, mRS 
and health-related quality of life). In order to  assess if the influence of endovascular 
treatment on Trail Making Test performance was relevant beyond physical disability, as 
a post-hoc analysis, cognitive outcome was evaluated separately in patients with 
good/poor functional outcome (mRS≤2/>2). 
 
Methods:  
Primary research question: Does thrombectomy improve Trail Making Test 
performance at 3 months after acute ischemic stroke due to an anterior large vessel 
occlusion?.  Classification of Evidence: This randomized interventional study provides 
Class I evidence that for patients with stroke from acute anterior circulation proximal 
arterial occlusion, thrombectomy improves performance on the Trail Making Test at 3 
months, when compared to best medical treatment alone. From November 2012 to 
December 2014, REVASCAT enrolled 206 patients with stroke of anterior circulation 
within 8 hours from onset that were randomized to receive thrombectomy (with 
Solitaire® device, Medtronic, ) or best medical treatment (both including intravenous 
rTPA). The trial was conducted in four comprehensive stroke centers of Catalonia, 
Spain. Patients with established dementia were excluded from enrollment. Detailed 
protocol and main results have been previously published. 8, 9 The trial was registered at 
Clinicaltrials.gov (NCT01692379) and funded by an unrestricted grant from the 
manufacturer of the device (Covidien, now Medtronic). Primary outcome of 
REVASCAT trial was distribution of functional outcome expressed as modified Rankin 
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scale (mRS) at 90 days. A pre-specified secondary objective was to test thrombectomy 
effects on cognitive function at three months and one year after randomization 9. 
Cognitive function was assessed in person by an investigator masked to treatment arm 
using Trail Making test (TMT) parts A and B. TMT measures attention, processing 
speed, working memory, visuospatial ability and set shifting 10.  TMT-A requires the 
patient to draw lines sequentially connecting 25 encircled numbers distributed on a 
sheet paper. In TMT-B the patient must alternate between numbers and letters (e.g., 1-
A-2-B-3-C…L-13). Before each test trial, a practice trial of six items was administered 
to ensure task understanding. Tests must be completed in a maximum of 5 minutes. 
During performance, each error was immediately corrected by the examiner and the 
patient was asked to continue the task. For each TMT-A and TMT-B cognitive outcome 
was evaluated by means of: 1) Percentage of patients that completed the tests in the 
requested time (5 minutes); 2) Time of completion of each test (in seconds); and 3) 
Number of errors made (none versus one or more errors). 
Infarct volumes (ml) at 24 hours on CT or MRI were adjudicated blinded to clinical data 
by an independent imaging core lab 8. Functional ability and health-related quality of 
life were evaluated at three months and one year after enrollment by masked certified 
assessors using mRS and EuroQoL Group 5-Dimension Self-Report Questionnaire (EQ-
5D) 3L, respectively. EQ-5D was analyzed using utility index adapted to Spanish 
population (range -0·3 to 1) and visual analogue scale (range 0 to 100), with higher 
values corresponding to better quality of life.  Language impairment and right upper 
limb paresis were evaluated with the specific NIH stroke scale items at three months 
after stroke. This specific data was not available at 1 year. 
Standard Protocol Approvals, Registrations, and Patient Consents:  REVASCAT 
trial received approval from ethical committees on human experimentation at the four 
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recruiting centers; written informed consent was obtained from all patients (or relatives) 
participating in the study; REVASCAT trial was registered at Clinicaltrials.gov 
(NCT01692379). 
 
Statistical analysis  
Main analyses were in the complete case population. The primary objective was to evaluate 
the effect of treatment arm on executive cognitive outcome at three months and one year after 
randomization. Differences in TMT completion on requested time (yes versus no) and 
presence of errors (0 versus ≥1) among treatment arms were assessed using logistic 
regression models, expressing the effect as odds ratio and 95% confident interval (CI). 
Difference in times of completion of TMT (seconds) among treatment arms was 
assessed using multivariate linear regression models, expressing the effect as the mean 
difference (B coefficient and 95% CI for B). To avoid missing data, maximum time of 
completion (300 seconds) was considered in those patients who could not complete the 
tests in the requested time. Multivariable analyses were adjusted by treatment arm, age, 
baseline stroke severity (NIHSS) and side of stroke. Association of Trail Making Test 
performance (completion times) with other outcome measures (infarct volume, mRS, 
EQ-5D) was assessed using Spearman Correlation coefficients.  
In order to assess if the influence of endovascular treatment on Trail Making Test 
performance was relevant beyond physical disability, differences in time of completion 
of TMT among treatment arms were evaluated separately in patients with mRS ≤2 and 
those with mRS >2. In this stratified analysis, differences were assessed using linear 
regression analysis. 
 
Results 
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Executive cognitive function was assessed in 82/84 thrombectomy and in 86/87 control 
patients alive at three months and in 71/79 thrombectomy and in 72/78 control patients 
alive at one year (see flow diagram on Figure 1). The percentage of patients that was 
able to complete TMT-A in due time (five minutes) was similar among treatment arms 
but thrombectomy increased around three folds the odds of timely TMT-B completion 
at three months and at one year after stroke (Table 1). Furthermore, patients assigned to 
thrombectomy required less time for tests completion and made fewer errors on TMT-A 
compared to those on medical arm (Table 1). 
Longer times to complete TMT were significantly associated with larger infarct volume, 
higher mRS scores and worse quality of life (Table 2).  
Among those patients who reached functional independency at three months (mRS ≤2), 
all except one completed TMT-A in the requested time in both treatment arms. TMT-B 
was completed in due time by around 69% of patients in thrombectomy arm and only in 
48% of patients in best medical treatment (Table 3). Differences in TMT completion 
times in favor of endovascular treatment were only significant in those patients who 
achieved a good functional outcome (mRS≤2) (Table 3 and Figure 2) and remained 
significant after adjustment for aphasic symptoms and paresis of right upper limb 
(among patients with a mRS≤2 at 3 months, only 9 had aphasic symptoms and only one 
patient had right hand paresis). 
 
Discussion 
Our study demonstrates that in patients with acute stroke due to a proximal large vessel 
occlusion, treatment with thrombectomy improves Trail Making Test performance, a 
measure of cognitive functioning, at three months and one year after stroke. These 
findings are important because they demonstrate that the benefit derived from 
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thrombectomy, only shown so far to affect disability and health related quality of life, 
also encompasses the cognitive domain.   
Because executive dysfunction is frequently found after stroke,1 we decided to evaluate 
this specific cognitive domain in REVASCAT. Trail Making Test is one of the most 
commonly used neuropsychological tests; it is easy and fast to administer and measures 
multiple executive functions simultaneously: attention, processing speed, set shifting, 
visuospatial ability and working memory.10 We found that the proportion of patients 
able to complete part A was similar among treatment arms, although patients treated 
with thrombectomy were less prone to make errors than control patients in this specific 
test and required shorter times for completion. These findings suggest less pronounced 
differences in processing speed and more substantial differences in attention and 
visuospatial abilities between thrombectomy patients and those patients assigned to 
medical treatment. Furthermore, thrombectomy also improves the completion of part B 
on requested time, a more complex task related to cognitive flexibility.11 Regarding time 
employed to complete the tests, linear regression analyses revealed significant 
differences in favor of thrombectomy in both tests. It is important to note that in our 
study, percentage of completion of part B in the requested time was low, so a high 
proportion of patients received the maximum time score (300 seconds).  Although this 
is a usual practice in administering Trail Making test, it masks performance variability 
among severely impaired patients who cannot complete the task. Therefore, some 
authors have tried to find scores that take into account not only time but also errors and 
correct moves.12 Because errors and moves were not collected in those patients who did 
not complete the test in the required time we were not able to investigate this aspect of 
cognitive performance which should be incorporated in future trials assessing the effect 
of reperfusion on the Trail Making Test.  
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In line with previous reports, we found that infarct volume was negatively correlated 
with executive functioning.13 Other relevant stroke outcome measures were significantly 
and directly correlated with poor cognitive status, such as health-related quality of life 
and disability status.  
In the stratified analysis by functional independence status, differences in TMT 
performance among treatment arms were only significant in those patients functionally 
independent (mRS ≤2). These findings may therefore justify the evaluation of cognitive 
outcomes in future stroke trials as it seems to provide relevant information beyond the 
widely used modified Rankin scale.  
There are several limitations to this study. First of all, sample size is smaller than 
projected because REVASCAT trial was stopped after first interim analysis, and the 
present study may be underpowered. Although established dementia was an exclusion 
criterion for enrollment in REVASCAT (because patients enrolled had to score 0 to 1 in 
mRS), we do not have precise information on pre-stroke cognitive functioning of 
included patients; therefore we cannot assure that the only factor influencing TMT 
performance was stroke itself. Analyses were adjusted for other co-variates that may 
influence understanding and ability to perform cognitive tasks (e.g age, stroke severity 
and side of stroke). However, data on education level, a factor known to significantly 
affect cognitive function, was not collected.  We do not believe that this limitation may 
alter conclusions since education level accounted only for 3% and 6% of the variance of 
TMA and TMB in a sample of 911 healthy volunteers.14Also, symptoms of 
depression/anxiety were only collected indirectly by EQ-5D and not included in 
multivariable models. Although we cannot assure the correct balance of pre-stroke 
cognitive status, educational level or depressive symptoms among treatment arms, the 
randomized nature of REVASCAT trial makes it at least possible. Finally, cognitive 
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outcome was evaluated only with two cognitive tests focused on executive functioning 
and therefore we cannot draw conclusions regarding other cognitive domains; we chose 
the Trail Making Test to evaluate cognition in REVASCAT due to its simplicity in 
administration and its established correlation with multiple cognitive dimensions. 
Furthermore, consensus regarding optimal measurement tools for post-stroke cognitive 
impairment is lacking. Major strengths of this study include its prospective nature, the 
randomized cohort of patients studied and the high rate of patients available for follow-
up.   
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Figure legends: 
 
Figure 1:  
Title: CONSORT flow diagram of patients included in REVASCAT trial 
Legend: The diagram shows patient allocation, deaths and missings for cognitive 
evaluation in each treatment arm and at both times of follow-up (three and 12 months 
after randomization) 
 
Figure 2:  
Title: TMT-A and TMT-B completion times stratified by functional outcome (mRS≤2 
and >2) in both treatment arms. 
Legend: Vertical axis represents completion times (seconds).  Arrows and lines 
represent mean and 95% CI of the mean. Grey arrows=endovascular treatment (EVT) 
and white arrows=best medical treatment (BMT). 3m=3 months; 1y= 1 year. P 
represents unadjusted mean difference (linear regression analysis) between treatment 
arms.  
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Figure 2: 
 
 
 
 
   
NEUROLOGY/2016/757195, López-Cancio 17 
 
Table 1. Cognitive outcomes in each treatment arm  
 
EVT: endovascular treatment. BMT: best medical treatment. TMT=Trail Making Test. Completion on due time refers 
to those that completed the test in less than 5 minutes. Time of completion is shown in seconds. Imputed times (300 
sec) in those patients not able to complete the tests in requested time. Values are expressed as number (percentage), 
and mean±standard deviation.1Adjusted by age, affected hemisphere and baseline stroke severity (NIHSS).  
 
 
 
 
  
 EVT+BMT BMT alone 
Effect  
measure 
Unadjusted value 
[95% CI] 
Adjusted value 
[95% CI] 1 
TMT-A 3 months (N)  82 86    
Completion on due time, n(%)  60 (73·2) 58 (67·4) Odds ratio 1·32[0·68,2·56] 1·48[0·71,3·11] 
Without errors, n(%)  47 (78·3) 34 (58·6) Odds ratio 2·55[1·14,5·71] 2·45[1·05,5·70] 
Time of completion (raw)  96·5±65·0 112·7±63·7 Mean diff 16·2[-7·3,39·7] 15·6[-6·3,37·6] 
Time of completion (imputed)  151·1±106·3 173·7±102·5 Mean diff 22·6 [-9·2, 54·4] 21·0 [-6·1,48·1] 
TMT-A 1 year (N)  71 72    
Completion on due time, n(%)  54 (76·0) 48 (66·7) Odds ratio 1·59[0·76,3·30] 2·00[0·87,4·61] 
Without errors, n(%)  44 (81·5) 30 (62·5) Odds ratio 2·64[1·07,6·50] 3·50[1·25,9·77] 
Time of completion (raw)  84·2±54·5 109·7±66·3 Mean diff 23·3 [0·4, 46·1] 23·4 [1·1, 45·8] 
Time of completion (imputed)  135·9±104·1 173·1±105·2 Mean diff 37·2 [2·6,71·8] 35·3 [4·5, 66·2] 
TMT-B  3 months (N)  82 86    
Completion on due time, n(%)  38 (46·3) 22 (25·6) Odds ratio 2·51[1·31,4·81] 3·17[1·51,6·66] 
Without errors, n(%)  15 (39·5)                 8 (36·4) Odds ratio 1·14[0·39,3·38] 1·05[0·33,3·38] 
Time of completion (raw)  155·6±68·7 173·9±71·7 Mean diff 18·3[-19·1,55·7] 22·9[-12·0,58·9] 
Time of completion (imputed)  233·1±86·0 267·7±65·8 Mean diff 34·6 [11·4,57·9] 32·1[11·9,52·3] 
TMT-B 1 year (N)  71 72    
Completion on due time, n(%)  36 (50·7) 19 (26·4) Odds ratio 2·87[1·42,5·78] 3·66[1·60,8·35] 
Without errors, n(%)  17 (47·2) 8 (42·1) Odds ratio 1·23[0·40,3·78] 0·93[0·28,3·09] 
Time of completion (raw)  153·4±71·4 132·9±70·3 Mean diff -20·5[-60·9,19·9] -18·0[-59·9,23·8] 
Time of completion (imputed)  225·6±89·5 255·9±82·2 Mean diff 30·2[1·9,58·6] 30·3[4·0,56·6] 
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Table 2. Spearman Correlation coefficients between TMT performance (completion 
times) and other outcome measures: infarct volume, functional outcome (mRS) and 
health-related quality of life (EQ-5D)  
 
 TMT-A 3m 
(n=168) 
TMT-A 1y 
(n=143) 
TMT-B 3m 
(n=168) 
TMT-B 1y 
(n=143) 
Infarct Volume (ml) 0·24 (0·002) 0·31 (<0·001) 0·35(<0·001) 0·29(<0·001) 
mRS  0·56 (<0·001) 0·60(<0·001) 0·53(<0·001) 0·51(<0·001) 
EQ-5D (VAS) -0·25(0·003) -0·32(0·001) -0·25(0·003) -0·17(0·074) 
EQ-5D (UI) -0·50(<0·001) -0·57(<0·001) -0·48(<0·001) -0·47(<0·001) 
Values are expressed as Spearman correlation coefficients (p). TMT=Trail Making Tests. 3m=3 months. 1y=1 year. 
Imputed values for completion times of TMT were used to avoid missing data in those participants that did not 
completed the tests on requested time. EQ-5D: EuroQoL Group 5-Dimension Self-Report Questionnaire 3L. VAS: 
visual analogue scale. UI: utility index. mRS: modified Rankin Scale score 
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Table 3. TMT performance in each treatment arm stratified by functional outcome 
(mRS≤2 and >2)  
 
 
EVT: endovascular treatment. BMT: best medical treatment. Effect is expressed as Mean Difference between 
treatment arms [95% CI] for completion times. Time of completion (sec=seconds, SD=standard deviation), using 
imputed values (300 sec) for those that were not able to complete the test on requested time. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Functionally independent 
(mRS≤2) 
 Functionally dependent 
(mRS>2) 
 
  EVT+BMT  BMT alone Effect SEVT+BMT  BMT alone Effect 
TMT-A 3 months (N)  45 29  37 57  
Completion on due time,n(%)  44 (98·7) 29 (100)  16(43·2) 29(50·9)  
Time of completion (sec±SD)  84·3±59·0 114·8±69·8 30·5[0·4,60·6], 
0·047 
232·3±93·9 203·6±104·0 -28·7[-70·7,13·3] 
0·178 
TMT-A 1 year (N)  39 27  32 45  
Completion on due time,n(%)  39 (100) 27 (100)  15 (46·9) 21(46·7)  
Time of completion (sec±SD)  70·6±45·5 99·5±62·7 28·9[2·3,55·5], 
0·034 
215·5±100·2 217·3±101·1 1·8[-44·6,48·2], 
0·939 
TMT-B  3 months (N)  45 29  37 57  
Completion on due time,n(%)  31 (68·9) 14 (48·3)  7(18·9) 8(14)  
Time of completion (sec±SD)  193·8±90·6 239·5±81·2 45·7[4·4,87·1], 
0·030 
280·9±48·5 282·1±51·5 1·2[-19·9,22·3], 
0·909 
TMT-B 1 year (N)  39 27  32 45  
Completion on due time,n(%)  30 (76·9) 13 (48·1)  6 (18·8) 6 (13·1)  
Time of completion (sec±SD)  176·9±88·3 217·1±97·7 40·2[-6·0,86·3], 
0·087 
285·0±43·3 279·2±61·4 -5·8[-31,19·3], 
0·647 
